Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
April 15, 2016Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
Pfizer fined for epilepsy drug price increase by UK antitrust regulator
April 15, 2016Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn
Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …
US annual spending on drugs rose 12.2% in 2015 – IMS
April 15, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending
The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer
April 15, 2016Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university
Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …
Synta Pharmaceuticals announces merger with Madrigal
April 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger
Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
Merck appoints Maya Martinez-Davis as global head of oncology
April 14, 2016Medical Communications Merck, maya martinez-davis, oncology
Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …
Merck says US FDA to review its Keytruda for head & neck cancer
April 14, 2016Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
Zika causes microcephaly and other birth defects, says CDC
April 14, 2016Medical Communications, Research and Development CDC, Zika, Zika virus, birth defects, microcephaly
The US Centers for Disease Control and Prevention has concluded that the Zika virus is a cause of microcephaly and …
Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
April 14, 2016Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
AbbVie announces positive Phase III results in hepatitis C drug
April 14, 2016Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III
AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …
NICE issues new guidance on the safer use of controlled drugs
April 13, 2016Medical Communications NICE, controlled drugs, guidance
The National Institute for Health and Care Excellence (NICE) has issued guidance bringing together legislation and existing advice on the …
Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
US FDA committee recommends against fast-track approval of Clovis’ cancer drug, asks for more data
April 13, 2016Medical Communications, Research and Development
Shares in Clovis Oncology Inc (Nasdaq: CLVS) closed down 5.4% Tuesday after the US Food and Drug Administration advisory committee recommended …
Structure of Zika virus revealed in new study
April 13, 2016Research and Development NIH, Purdue, Zika, glycoprotein, structure
Researchers have examined the structure of the Zika virus in a new study and found that is broadly similar to …
FDA accepts biologics license application for MSD’s allergy immunotherapy drug
April 13, 2016Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
Valeant bondholders issue notice to default
April 13, 2016Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility
Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
